About Cogent Biosciences, Inc. - Common Stock (COGT)
Cogent Biosciences Inc. is a biotechnology company focused on developing innovative therapies for genetically defined diseases. The company leverages its expertise in targeted drug development to create treatments that address the underlying genetic causes of various conditions, with a particular emphasis on rare diseases and severe forms of cancer. By utilizing advanced technologies and scientific research, Cogent aims to bring more effective therapeutic options to patients who are often underserved by existing treatments, advancing the field of precision medicine. Read More
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from its SUMMIT clinical trial for bezuclastinib. This investigational drug, aimed at non-advanced systemic mastocytosis (NonAdvSM), demonstrated significant efficacy and a favorable
Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential.
